We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Endometriosis Therapy Linked to Ovarian Cancer

By HospiMedica staff writers
Posted on 26 Mar 2002
A study has found that women taking danazol for treating endometriosis were nearly three times more likely to develop ovarian cancer than women taking leuprolide. More...
The study, conducted by researchers at the University of Pittsburgh Graduate School of Public Health (PA, USA) was presented at the annual meeting of the Society of Gynecologic Oncologists in Miami (FL, USA).

Danazol is a synthetic version of the male hormone androgen, while leuprolide is an anti-androgenic, gonadotropin-releasing hormone agonist. The study pooled data from two case-control studies that examined the relationship among endometriosis, endometriosis treatments, and ovarian cancer in 32 women. According to the researchers, previous studies have found that women with endometriosis already have a 50% increased risk for ovarian cancer. Treating them with danazol appeared to further increase their risk. Women who took leuprolide had no significant risk elevation.

"While the number of women studied is small, the results are telling, and they warrant further studies on a larger scale,” said Carrie Cottreau, Ph.D., assistant professor of obstetrics and gynecology at the University of Pittsburgh School of Medicine. Additional studies are planned.




Related Links:
Pitts.School of Public Health

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.